Search - tctmd.com

Displaying 41 - 60 of 127

Sort: Relevancy | Date

Thrombotic vs Bleeding Risks Post-TAVI: Insights From GALILEO

News Conference News EuroPCR 2022

Thrombotic vs Bleeding Risks Post-TAVI: Insights From GALILEO

Yael L. Maxwell

May 23, 2022

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

News Daily News

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

March 22, 2022

Hearts, Lungs, Kidneys: Mild-to-Moderate COVID-19 Leaves a Mark

News Daily News

Hearts, Lungs, Kidneys: Mild-to-Moderate COVID-19 Leaves a Mark

January 14, 2022

Age Not the Only Explanation for Sex Gap in PCI Care, Outcomes

News Daily News

Age Not the Only Explanation for Sex Gap in PCI Care, Outcomes

November 03, 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

News Conference News ESC 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

Michael O'Riordan

August 28, 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

News Conference News ESC 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

August 27, 2021

Prasugrel Tops Ticagrelor in ACS Across the eGFR Spectrum: ISAR-REACT 5

News Conference News ESC 2021

Prasugrel Tops Ticagrelor in ACS Across the eGFR Spectrum: ISAR-REACT 5

August 24, 2021

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

News Daily News

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

August 10, 2021

Final SPRINT Results Endorse Intensive BP Control

News Daily News

Final SPRINT Results Endorse Intensive BP Control

May 25, 2021

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

Renal Function Gains Seen in CKD Patients After TAVR

News Daily News

Renal Function Gains Seen in CKD Patients After TAVR

September 15, 2020

News Conference News ESC 2020

Dapagliflozin Wins in Patients With CKD

August 31, 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

September 16, 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

Endocarditis After TAVR: Real-world Data Speak to Its Rarity but Also the ‘Devastating’ Impact

News Conference News EuroPCR 2019

Endocarditis After TAVR: Real-world Data Speak to Its Rarity but Also the ‘Devastating’ Impact

June 07, 2019

A Look Back at TCT 2018: What I Took Away From the Meeting

News Opinion Fellow Talk

A Look Back at TCT 2018: What I Took Away From the Meeting

Yashasvi Chugh, MD

October 23, 2018

CTO PCI Patients With CKD Have More Acute Kidney Injury but Not Dialysis or TLF Over 2 Years

News Conference News TCT 2018

CTO PCI Patients With CKD Have More Acute Kidney Injury but Not Dialysis or TLF Over 2 Years

Yael L. Maxwell

September 23, 2018

Coronary Microvascular Dysfunction May Be a Marker of CV Risk in Obese Patients

News Daily News

Coronary Microvascular Dysfunction May Be a Marker of CV Risk in Obese Patients

August 09, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.